Esophageal Squamous Cell Cancer: A Chemo-Free Regimen Tempting for the Wrong Biomarker Result
A patient who wants to avoid chemotherapy is drawn to the one regimen that skips it entirely — the same regimen whose actual benefit was concentrated almost entirely in a biomarker result he doesn't have.
O.R., a 74-year-old man, spent most of his adult life as a long-haul trucker and still tows a small camper to fish the same lake every summer he can manage it, though this year's trip was cut short by worsening difficulty swallowing that finally sent him to a doctor. Endoscopy found a mid-esophageal mass, biopsy-confirmed squamous cell carcinoma, with staging CT showing pulmonary metastases — unresectable, metastatic disease. Tumor PD-L1 testing by tumor proportion score returned less than 1%, essentially negative. He watched a close friend go through chemotherapy for lung cancer two years ago and has said plainly, more than once in this visit alone, that he "doesn't want to spend whatever time he has left that sick."
CheckMate 648 tested two immunotherapy-containing strategies against chemotherapy alone in advanced esophageal squamous cell carcinoma: nivolumab added to chemotherapy, and a chemotherapy-free combination of nivolumab plus ipilimumab. Both improved overall survival in the trial's general population, but the two regimens' benefit was not evenly distributed by PD-L1 status — the chemotherapy-free nivolumab-ipilimumab combination's survival advantage was concentrated substantially in patients with PD-L1 tumor proportion score of 1% or higher, with a far more modest, less consistent signal below that threshold. Nivolumab added to chemotherapy, by contrast, showed benefit that held up more consistently across PD-L1 subgroups, including PD-L1-negative tumors like O.R.'s. The regimen he is most drawn to for its promise of avoiding chemotherapy altogether is, by his own tumor's biomarker profile, the one with the least consistent evidence actually behind it. His TPS of less than 1% is not a near-miss on the 1% line; it places him at the bottom of the very distribution the chemotherapy- free arm's advantage was concentrated above. What he watched happen to his friend is not a misunderstanding to be corrected, and the question in the room is what a patient is entitled to trade when the regimen he wants and the regimen his tumor answers to are not the same one.
First-line treatment planning, patient present for shared decision
CheckMate 648 (Doki et al., NEJM 2022) tested both regimens, and nivolumab plus chemotherapy's survival benefit held up across PD-L1 subgroups, including PD-L1-negative tumors like his. The chemotherapy-free nivolumab-ipilimumab combination's benefit was concentrated much more heavily in PD-L1-positive patients. I understand why he's drawn to skipping chemotherapy, but for his specific tumor biology, that's the option with the thinner evidence behind it.
I hear the evidence, and I'm not disputing the numbers. But he's told us clearly, more than once, that watching a friend go through chemotherapy shaped what he wants for himself — that's not a passing comment, it's a considered value. Some survival benefit was still seen in the PD-L1-negative subgroup on the chemo-free arm, even if smaller. A meaningfully worse quality of life on a marginally more effective regimen isn't automatically the right trade for every patient.
I'd also note his own functional status is already declining from dysphagia — that's relevant to how much added toxicity burden he can actually absorb either way.
I don't think we need to decide this for him. Tell him directly: nivolumab plus chemotherapy has the more consistent survival evidence for someone with his PD-L1 result; nivolumab plus ipilimumab avoids conventional chemotherapy but with a smaller, less certain benefit for his specific biomarker profile. Both are reasonable, guideline-supported choices. This is exactly the kind of decision where the actual data, stated plainly, should go to him rather than be resolved in this room on his behalf.
Agreed, after direct disclosure of both regimens' PD-L1-stratified outcomes: O.R. chose nivolumab plus ipilimumab, understanding explicitly that its survival benefit in patients with his PD-L1 result is smaller and less certain than the chemotherapy-containing option's.
The medical oncologist's evidence-based preference for the other regimen was not overridden by argument — it was set aside by an informed patient's own choice, made after the actual magnitude of the difference was stated plainly rather than softened. Imaging is planned at eight weeks with an explicit agreement to revisit chemotherapy addition promptly if there is no response.